Scholarlink

Objective <p>Low-grade serous carcinoma (LGSOC) constituting &lt; 15% of ovarian or peritoneal serous carcinomas differs distinctly from high-grade serous ovarian carcinoma (HGSOC). This global survey investigates the variations in managing LGSOC, acknowledging its unique characteristics and the absence of a consensus on optimal management.</p> Methods <p>A voluntary non-incentivized global survey gathered responses from 203 practitioners across 50 countries and 7 continents. Approved by the Institutional Ethics Committee, it encompassed 21 questions focusing on demographics, diagnosis, and management practices. Descriptive statistics and Fisher’s exact test analyzed the data.</p> Results <p>Demographically diverse responses were obtained with the majority from India (39.9%) and Colombia (5.4%). Gynecologic oncologists predominated (73.10%), with varied practice settings. Most practitioners considered LGSOC distinct (95.57%). Diagnosis criteria showed institutional variations. In managing apparent inoperable stage III C LGSOC approaches varied: neoadjuvant chemotherapy (54.78%), upfront surgery (35.69%), and neoadjuvant hormone therapy (8.54%). Adjuvant management demonstrated heterogeneity. Notably, there was no significant association between the continent and the offered adjuvant treatment for optimally cytoreduced stage III C LGSOC (<i>p</i> = 0.556; Fisher’s exact test). For recurrent disease, hormonal therapy (30.54%) and chemotherapy (27.59%) were common choices. MEK inhibitors were infrequently used. Fertility preservation was favored (71%), and HIPEC was not widely considered (81.28%). Genetic testing opinions varied: routine testing (28.7%), no recommendation (45.32%), and testing in recurrent settings (16.75%).</p> Conclusion <p>This survey exposes global disparities in LGSOC management, highlighting the need for standardized guidelines to address challenges in diagnosis and management. International collaboration is advocated to enhance uniformity in healthcare practices for LGSOC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Variations in the Management of Low-Grade Serous Carcinoma of the Ovary: A Global Survey

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2024年12月31日

查看全文
  • Biswajit Dash,
  • Geetu Bhandoria,
  • Seema Gulia,
  • Akshay Patil,
  • Amita Maheshwari

摘要

Objective

Low-grade serous carcinoma (LGSOC) constituting < 15% of ovarian or peritoneal serous carcinomas differs distinctly from high-grade serous ovarian carcinoma (HGSOC). This global survey investigates the variations in managing LGSOC, acknowledging its unique characteristics and the absence of a consensus on optimal management.

Methods

A voluntary non-incentivized global survey gathered responses from 203 practitioners across 50 countries and 7 continents. Approved by the Institutional Ethics Committee, it encompassed 21 questions focusing on demographics, diagnosis, and management practices. Descriptive statistics and Fisher’s exact test analyzed the data.

Results

Demographically diverse responses were obtained with the majority from India (39.9%) and Colombia (5.4%). Gynecologic oncologists predominated (73.10%), with varied practice settings. Most practitioners considered LGSOC distinct (95.57%). Diagnosis criteria showed institutional variations. In managing apparent inoperable stage III C LGSOC approaches varied: neoadjuvant chemotherapy (54.78%), upfront surgery (35.69%), and neoadjuvant hormone therapy (8.54%). Adjuvant management demonstrated heterogeneity. Notably, there was no significant association between the continent and the offered adjuvant treatment for optimally cytoreduced stage III C LGSOC (p = 0.556; Fisher’s exact test). For recurrent disease, hormonal therapy (30.54%) and chemotherapy (27.59%) were common choices. MEK inhibitors were infrequently used. Fertility preservation was favored (71%), and HIPEC was not widely considered (81.28%). Genetic testing opinions varied: routine testing (28.7%), no recommendation (45.32%), and testing in recurrent settings (16.75%).

Conclusion

This survey exposes global disparities in LGSOC management, highlighting the need for standardized guidelines to address challenges in diagnosis and management. International collaboration is advocated to enhance uniformity in healthcare practices for LGSOC.